The Patent Finder
IB

Immatics Biotechnologies GmbH

First filing 2002
OverviewNotableFeesChangesFamiliesPatent listSources & methods

476 patents currently held

2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jan 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
26
Ending by 2030
Jan 2027
Next term end
106
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Novel immunotherapy against several tumors including gastrointestinal and gastric cancer US 9,101,585
Cited by 129 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Ends Nov 2033 · High confidence
Also notable
Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Prostate Cancer and Other Cancers US 11,826,409
Cited by 17 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
Ends Aug 2036 · High confidence
Also notable
Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Small Cell Lung Cancer and Other Cancers US 10,253,077
Cited by 93 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2036.
Ends Nov 2036 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 3 fees due Nov 21 to 23, 2026 · next Nov 21
  • 14 fees due Dec 6 to 27, 2026 · next Dec 6
  • 15 fees due Jan 2 to 30, 2027 · next Jan 2
  • 19 fees due Feb 6 to 27, 2027 · next Feb 6
  • 7 fees due Mar 3 to 24, 2027 · next Mar 3
  • 22 fees due Apr 8 to 30, 2027 · next Apr 8
  • 23 fees due May 3 to 28, 2027 · next May 3
  • 12 fees due Jun 3 to 30, 2027 · next Jun 3
  • 20 fees due Jul 2 to 30, 2027 · next Jul 2
  • 17 fees due Aug 4 to 27, 2027 · next Aug 4
  • 22 fees due Sep 3 to 26, 2027 · next Sep 3
  • 15 fees due Oct 2 to 30, 2027 · next Oct 2
  • 8 fees due Nov 5 to 19, 2027 · next Nov 5

Which patents, and when each one lapses · Pro

Recent changes

  • 35 terms have ended since Aug 22, 2026

What they patent

The largest of its 106 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Peptides and Combination of Peptides of Non-Canonical Origin for Use in Immunotherapy Against Different Types of Cancers24 in forceto Feb 2039
Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, SCLC and Other Cancers23 in forceto May 2039
Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Esophageal Cancer and Other Cancers20 in forceto Jul 2036
Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Cancers18 in forceto Dec 2036
Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Prostate Cancer and Other Cancers17 in forceto Mar 2037

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 8,008,431Tumor-Associated Peptides That Bind to Mhc-Molecules
In force
 · High confidence
In forceHigh confidence
US 7,833,969Tumor-Associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules
In force
 · High confidence
In forceHigh confidence
US 7,833,970Tumor-Associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules
In force
 · High confidence
In forceHigh confidence
US 7,968,097Identification of HLA-A2-PRESENTED T-Cell Epitopes Derived from the Oncofoetal Antigen-Immature Laminin Receptor Protein and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,308,244Combination Therapy Using Active Immunotherapy
In force
 · High confidence
In forceHigh confidence
US 9,511,128Novel Immunogenic Epitopes for Immunotherapy
In force
 · High confidence
In forceHigh confidence
US 10,420,800Novel Immunotherapy Against Neuronal and Brain Tumors
In force
 · High confidence
In forceHigh confidence
US 10,434,120Novel Immunotherapy Against Neuronal and Brain Tumors
In force
 · High confidence
In forceHigh confidence
US 10,709,735Novel Immunotherapy Against Neuronal and Brain Tumors
In force
 · High confidence
In forceHigh confidence
US 11,648,276Novel Immunotherapy Against Neuronal and Brain Tumors
In force
 · High confidence
In forceHigh confidence
10 of 476 patents shown.
Pro members see all 476.
Pro members: see all 476 patents
Also on record, not counted in the 476: 2 patents in force now held by others · 257 patents ended · 91 applications pending · 197 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited